Manipulation of the Humoral Immune System and the Host Immune Response to Infection

Eric Wagner; Michael M. Frank

doi:10.1128/9781555818043.ch7

Chapter 7 : Manipulation of the Humoral Immune System and the Host Immune Response to Infection

Authors: Eric Wagner¹, Michael M. Frank²

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Departments of Pediatrics and Surgery, Duke University Medical Center, Durham, NC 27710; 2: Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC 27710

Content Type: Monograph

Publication Year: 2001

Category: Immunology

Book DOI: 10.1128/9781555818043

Chapter DOI: 10.1128/9781555818043.ch7

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Manipulation of the Humoral Immune System and the Host Immune Response to Infection, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555818043/9781555811679_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555818043/9781555811679_Chap07-2.gif

Abstract:

The humoral immune system comprises elements that, in part, provide protection against invading organisms. This chapter discusses the effects of manipulating the humoral immune system on the risk of developing microbial infections. Plasmapheresis (also called plasma exchange) has been utilized as a therapy for a limited number of immunological diseases that are caused by autoantibodies. Plasmapheresis has several possible benefits. First, plasma exchange may remove a portion of pathogenic autoantibodies. Second, removal of some circulating immune complexes may be achieved by plasmapheresis, although it has almost no effect on tissue-bound immune complexes that may be formed in situ. Specific methods, such as specific immunoadsorption methods, have been developed to remove specific pathogenic antibodies. Immunoadsorbents have been developed that remove immunoglobulins nonspecifically or that remove specific antibodies selectively. Elements of innate immunity such as natural antibodies and complement have clearly been shown to play an important role in host resistance against microorganisms. Experimental and clinical studies are needed to fully appreciate the beneficial and harmful effects of methods that interfere with unwanted pathologic effects of elements of the humoral immune system.

Citation: Wagner E, Frank M. 2001. Manipulation of the Humoral Immune System and the Host Immune Response to Infection, p 139-157. In Platt J (ed), Xenotransplantation. ASM Press, Washington, DC. doi: 10.1128/9781555818043.ch7

Highlighted Text: Show | Hide

Full text loading...

Figures

Manipulation of the Humoral Immune System and the Host Immune Response to Infection

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818043.chap7-1,webId=/content/author/10.1128/9781555818043.chap7-1,properties={foaf_givenname=Eric, foaf_name=Eric Wagner, foaf_surname=Wagner, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818043.chap7-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818043.chap7-2,webId=/content/author/10.1128/9781555818043.chap7-2,properties={foaf_givenname=Michael M., foaf_name=Michael M. Frank, foaf_surname=Frank, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818043.chap7-aff2]]}]]

/content/10.1128/9781555818043.chap7.fig7-1

Figure 1

Pathways of complement activation. Activators of complement such as microorganisms and antigen-antibody complexes bind the first component of each pathway to initiate activation of the entire cascade. Reactions beyond C3 activation are common to all three pathways and result in the formation of the C5-9 complex known as the membrane attack complex. C, complement component; MBL, mannan-binding lectin; MASP, mannan-binding lectin-associated serine protease; C3(H2O), C3 that underwent spontaneous hydrolysis of its thiolester group; B, factor B; D, factor D; P, properdin.

10.1128/9781555818043/fig7-1_thmb.gif

10.1128/9781555818043/fig7-1.gif

Figure 1

References

/content/book/10.1128/9781555818043.chap7

1. Ahlstedt, S. 1981. Experimental Escherichia coli 06 infection in mice. Acta Pathol. Microbiol. Scand. 89( C): 23– 28.

2. Alarabi, A. A.,, B. Nilsson,, U. Nilsson,, B. Wikstrom,, and B. G. Danielson. 1993. Complement activation during tryptophan immunoadsorption treatment. Artif. Organs 17: 782– 786.

3. Alarabi, A.,, U. Backman,, O. Wikstrom Sjoberg,, and G. Tufveson. 1997. Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Int. J. Artif. Organs 20: 51– 56.

4. Aoki, T.,, M. J. Walling,, G. S. Bushar,, M. Liu,, and K. C. Hsu. 1976. Natural antibodies in sera from healthy humans to antigens on surfaces of type C RNS viruses and cells from primates. Proc. Natl. Acad. Sci. USA 73: 2491– 2495.

5. Aringer, M.,, J. S. Smolen,, and W. B. Graninger. 1998. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum. 41: 414– 420.

6. Avrameas, S. 1991. Natural antibodies: from "horror autotoxicus" to "gnothi seauton." Immunol. Today 12: 154– 159.

7. Basta, M. 1996. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin. Exp. Immunol. 104( Suppl. l): 21– 25.

8. Basta, M.,, and M. C. Dalakas. 1994. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94: 1729– 1735.

9. Basta, M.,, P. Kirshbom,, M. M. Frank,, and L. F. Fries. 1989. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 84: 1974– 1981.

10. Beebe, D. P.,, and N. R. Cooper. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126: 1562– 1568.

11. Berglin, E.,, C. Kjellstrom,, V. Mantovani,, G. Stelin,, C. Svalander,, and L. Wiklund. 1995. Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Transplant Int. 8: 382– 387.

12. Bitter-Suermann, D.,, and R. Burger. 1986. Guinea pigs deficient in C2, C4, C3 or the C3a receptor. Prog. Allergy 39: 134– 158.

13. Boyden, S. 1964. Natural antibodies and the immune response. Adv. Immunol. 5: 1– 28.

14. Brauer, R. B.,, W. M. Baldwin III,, S. Ibrahim,, and F. Sanfilippo. 1995. The contribution of the terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 59: 288– 293.

15. Briles, D.,, M. Nahm,, K. Schroer,, J. Davie,, P. Baker,, J. Kearney,, and R. Barlettas. 1981. Antiphospho-choline antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153: 694– 705.

16. Brown, E. J.,, M. Berger,, K. A. Joiner,, and M. M. Frank. 1983. Classical pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect. Immun. 42: 594– 598.

17. Brown, E. J.,, S. W. Hosea,, and M. M. Frank. 1981. Reticuloendothelial clearance of radiolabeled pneumococci in experimental bacteremia: correlation of changes in clearance rates, sequestration patterns, and opsonization requirements at different phases of the bacterial growth cycle. J. Reticuloendothelial Soc. 30: 23– 31.

18. Brown, E. J.,, S. W. Hosea,, and M. M. Frank. 1981. The role of the spleen in experimental pneumococcalbacteremia. J. Clin. Invest. 67: 975– 982.

19. Brown, E. J.,, S. W. Hosea,, C. H. Hammer,, C. G. Burch,, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Invest. 69: 85– 98.

20. Budzko, D. B.,, M. C. Pizzimenti,, and F. Kierszenbaum. 1975. Effects of complement depletion in ex-perimental Chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi. Infect. Immun. 11: 86– 91.

21. Buerke, M.,, T. Morohara,, and A. M. Lefer. 1995. Cardioprotective effects of a CI esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393– 402.

22. Candinas, D.,, B.-A. Lesnikoski,, S. C. Robson,, T. Miyatake,, S. M. Scesney,, H. C. Marsh, Jr.,, U. S. Ryan,, A. P. Dalmasso,, W. W. Hancock,, and F. H. Bach. 1996. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 62: 336– 342.

23. Casali, P.,, and A. L. Notkins. 1989. CD5+ B lymphocytes, polyreactive antibodies and the human B cell repertoire. Immunol. Today 10: 364– 368.

24. Casali, P.,, and E. W. Schettino. 1996. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210: 167– 179.

25. Challacombe, S. J.,, L. A. Bergmeier,, C. Czerkinsky,, and A. S. Rees. 1984. Natural antibodies in man to Streptococcus mutans: specificity and quantification. Immunology 52: 143– 150.

26. Chopek, M.,, and J. McCulIogh,. 1980. Protein and biochemical changes during plasma exchange, p. 13– 52. In J. Ulmas, and B. Berkman (ed.), Therapeutic Haemapheresis: A Technical Workshop. American Association of Blood Banks, Washington, D.C.

27. Cooper, N. R., 1998. Complement and viruses, p. 393– 407. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.

28. Dalmasso, A. P. 1992. The complement system in xenotransplantation. Immunopharmacology 24: 149– 160.

29. Dalmasso, A. P.,, and J. L. Platt 1993. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by CI inhibitor. Transplantation 56: 1171– 1176.

30. Dalmasso, A. P.,, G. M. Vercellotti,, R. J. Fischel,, R. M. Bolman,, F. H. Bach,, and J. L. Platt. 1992. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am. J. Pathol. 140: 1157– 1166.

31. Davis, E. A.,, S. K. Pruitt,, P. S. Greene,, S. Ibrahim,, T. T. Lam,, J. L. Levin,, W. M. Baldwin D3,, and F. Sanfllippo. 1996. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 62: 1018– 1023.

32. Densen, P., 1998. Complement deficiencies and infection, p. 409– 421. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.

33. Dwyer, J. M. 1992. Manipulating the immune system with immune globulin. N. Engl. J. Med. 326: 107– 116.

34. Epstein, J.,, Q. Eichbaum,, S. Sheriff,, and R. A. B. Ezekowitz. 1996. The collectins in innate immunity. Curr. Opin. Immunol. 8: 29– 35.

35. Evans, M. J.,, S. A. Rollins,, D. W. Wolff,, R. P. Rother,, A. J. Norin,, D. M. Therrien,, G. A. Grijalva,, J. P. Mueller,, S. H. Nye,, S. P. Squinto,, and J. A. Wilkins. 1995. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol. Immunol. 32: 1183– 1195.

36. Farges, O.,, A. N. Kalil,, D. Samuel,, F. Saliba,, J. L. Arulnaden,, P. Debat,, A. Bismuth,, D. Castaing,, and H. Bismuth. 1995. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 59: 1124– 1133.

37. Fearon, D. T. 1984. Cellular receptors for fragments of the third component of complement. Immunol. Today 5: 105– 110.

38. Figueroa, J. E.,, and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4: 359– 395.

39. Fishelson, Z. 1994. Complement-related proteins in pathogenic organisms. Springer Semin. Immunopathol. 15: 345– 368.

40. Fisher, M. B.,, A. P. Prodeus,, A. Nicholson-Weller,, M. Ma,, J. Murrow,, R. R. Reid,, H. B. Warren,, L. Lage,, F. D. Moore, Jr.,, F. S. Rosen,, and M. C. Carroll. 1997. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159: 976– 982.

41. Frank, M. M. 1995. Animal models for complement deficiencies. J. Clin. Immunol. 15: 113S– 121S.

42. Frank, M. M.,, and L. F. Fries,. 1989. Complement, p. 679– 701. In W. E. Paul (ed.), Fundamental Immunology, 2nd ed. Raven Press, Ltd., New York, N.Y.

43. Frank, M. M.,, and L. F. Fries. 1998. The role of complement in defence against bacterial disease. Bailliere's Clin. Immunol. Allergy 2: 335– 361.

44. Frank, M. M.,, K. A. Joiner,, and C. H. Hammer. 1987. The function of antibody and complement in thelysis of bacteria. Rev. Infect. Dis. 9: S537– S545.

45. Galili, U. 1993. Evolution and pathophysiology of the human natural anti-galactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15: 155– 171.

46. Goes, A. M.,, and F. J. Ramalho-Pinto. 1991. Protective immunity to Schistosoma mansoni in mice is dependent on antibody and complement but not on radiosensitive leukocytes. Immunol. Lett. 28: 57– 64.

47. Griffin, S. V.,, C. M. Lockwood,, and C. D. Pusey,. 1996. Plasmapheresis and immunoadsorption, p. 636– 651. In K. F. Austen,, S. J. Burakoff,, F. S. Rosen,, and T. B. Strom (ed.), Therapeutic Immunology. Blackwell Science, Inc., Cambridge, Mass.

48. Harindranath, N.,, H. Ikematsu,, A. L. Notkins,, and P. Casali. 1993. Structure of the V H and V L segments of polyreactive and monoreactive human natural antibodies to HIV-1 and Escherichia coli β-galactosidase. Int. Immunol. 5: 1523– 1533.

49. Higgins, R. M.,, D. J. Bevan,, B. S. Carey,, C. K. Lea,, M. Fallon,, R. Buhler,, R. W. Vaughan,, P. J. O'Donnell,, S. A. Snowden,, M. Bewick,, and B. M. Hendry. 1996. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 348: 1208– 1211.

50. Hirsh, R. L.,, D. E. Griffin,, and J. A. Winkelstein. 1978. The effect of complement depletion on the course of sindbis virus infection in mice. J. Immunol. 121: 1276– 1278.

51. Horowitz, J.,, J. E. Volanakis,, and D. E. Briles. 1987. Blood clearance of Streptococcus pneumoniae by C-reactive protein. J. Immunol. 138: 2598– 2603.

52. Ishiwaka, A.,, M. Itoh,, T. Ushlyama,, K. Suzuki,, and K. Fujita. 1998. Experience of ABO-incompatible living kidney transplantation after double filtration plasmapheresis. Clin. Transplant. 12: 80– 83.

53. Jakobs, F. M.,, E. A. Davis,, T. White,, F. Sanfilippo,, and W. M. Baldwin III. 1998. Prolonged discordant xenograft survival by inhibition of the intrinsic coagulation pathway in complement C6-deficient recipients. J. Heart Lung Transplant. 17: 306– 311.

54. Kalli, K. R.,, P. Hsu,, and D. T. Fearon. 1994. Therapeutic uses of recombinant complement protein inhibitors. Semin. Immunopathol. 15: 417– 431.

55. Kantor, A. B. 1991. The development and repertoire of B-l cells (CD5 B cells). Immunol. Today 12: 389– 391.

56. Kaplan, M. H.,, and J. E. Volanakis. 1974. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J. Immunol. 112: 2135– 2147.

57. Kearns-Jonker, M.,, M. Fraiman,, W. Chu,, E. Gochi,, J. Michel,, G.-D. Wu,, and D. V. Cramer. 1998. Xenoantibodies to pig endothelium are expressed in germline configuration and share a conserved immunoglobulin V H gene structure with antibodies to common infectious agents. Transplantation 5: 1515– 1519.

58. Kemp, E. 1996. Xenotransplantation. J. Intern. Med. 239: 287– 297.

59. Kirschfink, M. 1997. Controlling the complement system in inflammation. Immunopharmacology 38: 51– 62.

60. Klickstein, L. B.,, T. J. Bartow,, V. Miletic,, L. D. Rabson,, J. A. Smith,, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168: 1699– 1717.

61. Konishi, E.,, and M. Nakao. 1992. Naturally occurring immunoglobulin M antibodies: enhancement of phagocytic and microbicidal activities of human neutrophils against Toxoplasma gondii. Parasitology 104: 427– 432.

62. Kozel, T. R. 1996. Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev. 9: 34– 46.

63. Kroshus, T. J.,, S. A. Rollins,, A. P. Dalmasso,, E. A. Elliott,, L. A. Matis,, S. P. Squinto,, and R. M. Bolman HI. 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60: 1194– 1202.

64. Leventhal, J. R.,, A. P. Dalmasso,, J. W. Cromwell,, J. L. Platt,, C. J. Manivel,, R. M. Bolman HI,, and A. J. Matas. 1993. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55: 857– 866.

65. Leventhal, J. R.,, R. John,, J. P. Fryer,, J. C. Witson,, J.-M. Derlich,, J. Remiszewski,, A. P. Dalmasso,, A. J. Matas,, and R. M. Bolman III. 1995. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation 59: 294– 300.

66. Leventhal, R.,, H. Bonner,, E. J. L. Soulsby,, and A. D. Schreiber. 1978. The role of complement in Ascaris suum induced histopathology. Clin. Exp. Immunol. 32: 69– 76.

67. Lin, S. S.,, D. L. Kooyman,, L. J. Daniels,, C. W. Daggett,, W. Parker,, J. H. Lawson,, C. W. Hoopes,, C. Gullotto,, L. Li,, P. Birch,, R. D. Davis,, L. E. Diamond,, J. S. Logan,, and J. L. Platt. 1997. The role of natural anti-gala l-3gal antibodies in hyperacute rejection of pig-to-baboon cardiac transplants. Transplant. Immunol. 5: 212– 218.

68. Lutz, H. U.,, P. Stanunler,, E. Jelezarova,, M. Nater,, and P. J. Spath. 1996. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in (C3b)n-IgG complexes. Blood 88: 184– 193.

69. Lydyard, P. M.,, A. Lamour,, L. E. MacKenzie,, C. Jamin,, R. A. Mageed,, and P. Youinou. 1993. CD5+ B cells and the immune system. Immunol. Lett. 38: 159– 166.

70. Magee, J. C.,, B. H. Collins,, R. C. Harland,, B. J. Lindman,, R. R. Bollinger,, M. M. Frank,, and J. L. Platt 1995. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J. Clin. Invest. 96: 2404– 2412.

71. Makrides, S. C. 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50: 59– 87.

72. Marsh, J. E.,, M. C. Carroll,, and S. H. Sacks. 1998. The classic pathway augments production of alloantibodies. Mol. Immunol. 35: 393.

73. Matsushita, M.,, and T. Fujita. 1996. The lectin pathway. Res. Immunol. 147: 115– 118.

74. May, J. E.,, M. A. Kane,, and M. M. Frank. 1972. Host defense against bacterial endotoxemia. Contribution of the early and late components of complement to detoxification. J. Immunol. 109: 893– 895.

75. Michael, J. G. 1969. Natural antibodies. Curr. Top. Microbiol. Immunol. 48: 43– 62.

76. Miletic, V. D.,, C. G. Hester,, and M. M. Frank. 1996. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J. Immunol. 156: 749– 757.

77. Miller, T. E.,, S. Phillips,, and T. J. Simpson. 1978. Complement-mediated immune mechanisms in renal infection, n. Effect of decomplementation. Clin. Exp. Immunol. 33: 115– 121.

78. Miyagawa, S.,, R. Shirakura,, G. Matsumiya,, N. Fukushima,, S. Nakata,, H. Matsuda,, M. Matsumoto,, H. Kitamura,, and T. Seya. 1993. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT-175. Transplantation 55: 709– 713.

79. Mokrzycki, M. H.,, and A. A. Kaplan. 1994. Therapeutic plasma exchange: complications and management. Am. J. Kidney Dis. 23: 817– 827.

80. Mollnes, T. E.,, K. Hogasen,, B. F. Hoaas,, T. E. Michaelsen,, P. Garred,, and M. Harboe. 1995. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding preperties. Scand. J. Immunol. 41: 449– 456.

81. Moore, F. D., Jr.,, D. T. Fearon,, and K. F. Austen. 1981. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J. Immunol. 126: 1805– 1809.

82. Mor, E.,, D. Skerrett,, C. Manzarbeitia,, P. A. Sheiner,, M. E. Schwartz,, S. Emre,, S. N. Thung,, and C. M. Miller. 1995. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 59: 986– 990.

83. Morgan, B. P. 1995. Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32: 265– 298.

84. Morgan, B. P.,, and S. Meri. 1994. Membrane proteins that protect against complement lysis. Semin. Immunopathol. 15: 369– 396.

85. Mouthon, L.,, S. V. Kaveri,, S. H. Spalter,, S. Lacroix-Desmazes,, C. Lefranc,, R. Desai,, and M. D. Kazatchkine. 1996. Mechanism of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104( Suppl. l): 3– 9.

86. Naik, R. B.,, R. Ashlin,, C. Wilson,, D. S. Smith,, H. A. Lee,, and M. Slapak. 1979. The role of plasmapheresis in renal transplantation. Clin. Nephrol. 11: 245– 250.

87. Norrgren, K.,, S. E. Strand,, and C. Ingvar. 1992. Contrast enhancement in RII and modification of the therapeutic ratio in RIT: a theoretical evaluation of simulated extracorporeal immunoadsorption. Antibody Immunoconj. Radiopharmaceut. 5: 61– 73.

88. Ohta, H.,, Y. Yoshikawa,, C. Kai,, K. Yamanouchi,, H. Taniguchi,, K.-I. Komine,, Y. Ishijima,, and H. Okada. 1986. Effect of complement depletion by cobra venom factor on fowlpox virus infection in chickens and chicken embryos. J. Virol. 57: 670– 673.

89. Olivari, M.-T.,, C. B. May,, N. A. Johnson,, W. S. Ring,, and M. K. Stephens. 1994. Treatment of acute vascular rejection with immunoadsorption. Circulation 90: 1170– 1173.

90. Olsen, S. L.,, L. E. Wagoner,, E. H. Hammond,, D. O. Taylor,, R. L. Yowell,, R. D. Ensley,, M. R. Bristow,, J. B. O'Connell,, and D. G. Renlund. 1993. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J. Heart Lung Transplant. 12: S135– S142.

91. Pangburn, M. K.,, and H. J. Müller-Eberhard. 1984. The alternative pathway of complement. Semin. Immunopathol. 7: 163– 192.

92. Parker, W.,, D. Bruno,, and J. L. Platt. 1995. Xenoreactive antibodies in the world of natural antibodies: typical or unique? Transplant. Immunol. 3: 181– 191.

93. Petry, F.,, and M. Loos,. 1998. Bacteria and complement, p. 375– 391. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.

94. Platt, J. L., 1995. Natural antibodies, p. 55– 80. In J. L. Platt (ed.), Hyperacute Xenograft Rejection. R.G. Landes Co., Georgetown, Tex.

95. Platt, J. L. 1998. New directions for organ transplantation. Nature 392: 11– 17.

96. Platt, J. L.,, S. S. Lin,, and C. G. A. McGregor. 1998. Acute vascular rejection. Xenotransplantation 5: 169– 175.

97. Pohl, M. A.,, S.-P. Lan,, T. Berl, and the Lupus Nephritis Collaborative Study Group. 1991. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann. Intern. Med. 114: 924– 929.

98. Poulle, M.,, M. Burnouf-Radosevich,, and T. Burnouf. 1994. Large-scale preparation of highly purified human CI inhibitor for therapeutic use. Blood Coagul. Fibrinolysis 5: 543– 549.

99. Pratt, J. R.,, A. W. Harmer,, J. Levin,, and S. H. Sacks. 1997. Influence of complement on the allospecific antibody response to a primary vascularized organ graft. Eur. J. Immunol. 27: 2848– 2853.

100. Pratt, J. R.,, M. J. Hibbs,, A. J. Laver,, A. G. Smith,, and S. H. Sacks. 1996. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol. 149: 2055– 2066.

101. Pretagostini, R.,, P. Berloco,, L. Poli,, P. Cinti,, A. Di Nicuolo,, P. De Simone,, M. Colonnello,, A. Salerno,, D. Alfani,, and R. Cortesini. 1996. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J. 42: M645– M648.

102. Pruitt, S. K.,, A. D. Kirk,, R. R. Bollinger,, H. C. Marsh, Jr.,, B. H. Collins,, J. L. Levin,, J. R. Mault,, J. S. Heinle,, S. Ibrahim,, A. R. Rudolph,, V. M. Baldwin III,, and F. Sanfllippo. 1994. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363– 370.

103. Qi, M.,, and J. A. Shifferli. 1995. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum. 38: 146.

104. Qian, Z.,, F. M. Jakobs,, T. Pfaff-Amesse,, F. Sanfllippo,, and W. M. Baldwin III. 1998. Complement contributes to the rejection of complete and class I major histocompatibility complex-incompatible cardiac allografts. J. Heart Lung Transplant. 17: 470– 478.

105. Reid, R. R.,, A. P. Prodeus,, W. Khan,, T. Hsu,, F. S. Rosen,, and M. C. Carroll. 1997. Endotoxin shock in antibody-deficient mice. Unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159: 970– 975.

106. Ritter, K.,, A. Fudickar,, N. Heine,, and R. Thomssen. 1997. Autoantibodies with a protective function: polyreactive antibodies against alkaline phosphatase in bacterial infections. Med. Microbiol. Immunol. 186: 109– 113.

107. Rodman, T. C.,, S. E. To,, J. J. Sullivan,, and R. Winston. 1997. Innate natural antibodies. Primary roles indicated by specific epitopes. Hum. Immunol. 55: 87– 95.

108. Rollins, S. A.,, J. C. K. Fitch,, S. Sherman,, C. S. Rinder,, H. M. Rinder,, B. R. Smith,, C. D. Collard,, G. L. Stahl,, B. L. Alford,, L. Li,, and L. A. Matis. 1998. Anti-C5 single chain antibody therapy blocks complement and leukocyte activation and reduces myocardial tissue damage in CPB patients. Mol. Immunol. 35: 397.

109. Rollins, S. A.,, L. A. Matis,, J. P. Springhorn,, E. Setter,, and D. W. Wolff. 1995. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 60: 1284– 1292.

110. Saadi, S.,, and J. L. Platt 1998. Immunology of xenotransplantation. Life Sci. 62: 365– 387.

111. Salmela, K. T.,, E. O. von Willebrand,, L. E. Kyllonen,, B. H. Eklund,, K. A. Hockerstedt,, H. M. Isoniemi,, L. Krogerus,, E. Taskinen,, and P. J. Ahonen. 1992. Acute vascular rejection in renal transplantation: diagnosis and outcome. Transplantation 54: 858– 862.

112. Sanaka, T.,, S. Wakai,, S. Teraoka,, T. Takuma,, N. Sugino,, and T. Agishi,. 1990. Effect of therapeutic plasma exchange on immunological and renal pathological findings in patients with lupus nephritis, p. 351– 353. In G. Rock (ed.), Apharesis. Alan R. Liss, Inc., New York, N.Y.

113. Sato, Y.,, M. Kimikawa,, H. Suga,, Y. Hayasaka,, S. Teraoka,, T. Agishi,, and K. Ota. 1992. Prolongation of cardiac xenograft survival by double filtration plasmapheresis and ex vivo immunoadsorption. ASAIO J. 38: M673– M675.

114. Schneider, K. M. 1998. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int. 53: S61– S65.

115. Schreiber, J. R.,, C. Basker,, and G. R. Siber. 1987. Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b. Infect. Immun. 55: 2830– 2833.

116. Schweinle, J. E.,, R. A. B. Ezekowitz,, A. J. Tenner,, M. Kuhlman,, and K. A. Joiner. 1989. Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J. Clin. Invest. 84: 1821– 1829.

117. Silverstein, A. M., 1993. The history of immunology, p. 21– 41. In W. E. Paul (ed.), Fundamental Immunology, 3rd ed. Raven Press, Ltd., New York, N.Y.

118. Snyder, H. W.,, and E. Fleissner. 1980. Specificity of human antibodies to oncovirus glycoproteins: recognition of antigen by natural antibodies directed against carbohydrate structures. Proc. Natl. Acad. Sci. USA 77: 1622– 1626.

119. Sonnenwirth, A. C. 1979. Antibody response to anaerobic bacteria. Rev. Infect. Dis. 1: 337– 341.

120. Stegmayr, B. G. 1996. Plasmapheresis in severe sepsis or septic shock. Blood Purif. 14: 94– 101.

121. Stiehm, E. R.,, T. W. Chin,, A. Haas,, and A. G. Peerless. 1986. Infectious complications of the primary immunodeficiencies. Clin. Immunol. Immunopathol. 40: 69– 86.

122. Strauss, R. G.,, D. Clavarella,, R. O. Gilcher,, D. O. Kasprisin,, D. D. Kiprov,, H. G. Klein,, and B. C. McLoed. 1993. An overview of current management. J. Clin. Apharesis 8: 189– 194.

123. Suankratay, C.,, X.-H. Zhang,, Y. Zhang,, T. F. Lint,, and H. Gewurz. 1998. Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. J. Immunol. 160: 3006– 3013.

124. Swift, A. J.,, T. S. Collins,, P. Bugelski,, and J. A. Winkelstein. 1994. Soluble complement receptor type 1 inhibits complement-mediated host defense. Clin. Diagn. Lab. Immunol. 1: 585– 589.

125. Szalai, A. J.,, D. E. Briles,, and J. E. Volanakis. 1996. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect. Immun. 64: 4850– 4853.

126. Tanaka, M.,, N. Murase,, Q. Ye,, W. Miyazaki,, M. Nomoto,, H. Miyazawa,, R. Manez,, Y. Toyama,, A. J. Demetris,, S. Todo,, and T. E. Starzl. 1996. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. Transplantation 62: 681– 688.

127. Taniguchi, S.,, S. Kitamura,, K. Kawachi,, M. Fukutomi,, Y. Yoshida,, and Y. Kondo. 1992. Effects of double-filtration plasmapheresis and a platelet-activating factor antagonist on the prolongation of xenograft survival. J Heart Lung Transplant. 11: 1200– 1208.

128. Thiel, S.,, T. Vorup-Jensen,, C. M. Stover,, W. Schwaeble,, S. B. Laursen,, K. Poulsen,, A. C. Willis,, P. Eggelton,, S. Hansen,, U. Holmskov,, K. B. M. Reid,, and J. C. Jensenius. 1997. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 606– 610.

129. Thomas, T. C.,, S. A. Rollins,, R. P. Rother,, M. A. Giannoni,, S. L. Hartman,, E. A. Elliott,, S. H. Nye,, L. A. Matis,, S. P. Squinto,, and M. J. Evans. 1996. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33: 1389– 1401.

130. TJlanova, M.,, M. Hahn-Zoric,, Y. L. Lau,, A. Lucas,, and L. A. Hanson. 1996. Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies. Clin. Exp. Immunol. 105: 422– 428.

131. van Emmerik, L. C.,, E. J. Kuljper,, C. A. P. Fyen,, J. Dankert,, and S. Thiel. 1994. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin. Exp. Immunol. 97: 411– 416.

132. Vogel, C. W.,, and H. J. Müller-Eberhard. 1982. The cobra venom factor-dependent C3 convertase of human complement. J. Biol. Chem. 257: 8292– 8299.

133. Volanakis, J. E.,, and M. M. Frank (ed.). 1998. The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.

134. Wagner, E.,, and M. M. Frank,. 1998. Development of clinically useful agents to control complement-mediated tissue damage, p. 527– 546. In J. E. Volanakis, and M. M. Frank (ed.), The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York, N.Y.

135. Wagner, E.,, J. L. Platt,, and M. M. Frank. 1998. High dose intravenous immunoglobulin does not affect complement-bacteria interactions. J. Immunol. 160: 1936– 1943.

136. Wang, Y.,, Q. L. Hu,, J. A. Madri,, S. A. Rollins,, A. Chodera,, and L. A. Matis. 1995. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93: 8563– 8568.

137. Wang, Y.,, S. A. Rollins,, J. A. Madri,, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92: 8955– 8959.

138. Waytes, A. T.,, F. S. Rosen,, and M. M. Frank. 1996. Treatment of angioedema with a vapor-heated CI inhibitor concentrate. N. Engl. J. Med. 334: 1630– 1634.

139. Webster, A. D. B.,, G. P. Spickett,, B. J. Thompson,, and J. Farrant. 1988. Viruses and antibody deficiency syndromes. Immunol. Invest. 17: 93– 105.

140. Weisman, H. E.,, T. Bartow,, M. K. Leppo,, H. C. Marsh, Jr.,, G. R. Carson,, M. F. Concino,, M. P. Boyle,, K. H. Roux,, M. L. Weisfeldt,, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146– 151.

141. Wu, M. J.,, K. H. Shu,, C. H. Cheng,, and J. D. Lian. 1997. Complications of membrane-filtration plasma exchange. Chung Hual Shueh Chih (Taipei) 60: 147– 154.

142. Zhang, W.,, and P. J. Lachman. 1994. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology 81: 137– 141.